Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.78%
1,084.28
-8.52
-0.78%
—1,092.801,093.681,094.851,081.97——
SIXC
Communications
SIXC
Communications
SIXC
-0.29%
602.97
-1.77
-0.29%
—604.74604.74605.10601.34——
SIXE
Energy
SIXE
Energy
SIXE
+2.03%
1,239.40
+24.60
+2.03%
—1,214.801,220.811,243.821,220.81——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.78%
1,711.14
-13.43
-0.78%
—1,724.571,727.021,732.301,707.43——
SIXM
Financials
SIXM
Financials
SIXM
+0.16%
640.46
+1.03
+0.16%
—639.43641.58644.53637.50——
SIXR
Staples
SIXR
Staples
SIXR
-0.39%
835.85
-3.30
-0.39%
—839.15836.90840.48832.89——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.63%
214.26
-1.36
-0.63%
—215.62215.62216.21213.48——
SIXT
Technology
SIXT
Technology
SIXT
+0.52%
3,195.98
+16.46
+0.52%
—3,179.523,191.503,205.093,177.75——
SIXU
Utilities
SIXU
Utilities
SIXU
-1.24%
925.31
-11.60
-1.24%
—936.91935.42937.17923.20——
SIXV
Health care
SIXV
Health care
SIXV
-0.71%
1,442.50
-10.27
-0.71%
—1,452.771,445.931,447.431,434.91——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.31%
2,357.81
-7.37
-0.31%
—2,365.182,353.642,368.102,347.80——
LGDN:FRA
Ligand Pharmaceuticals Inc
€192.00
-4.95%
(-10.00) 1D
Apr 29, 3:44:26 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LGDN...
Open
€198.00
High
€198.00
Low
€192.00
Mkt. cap
4.52B
Avg. vol.
3.00
Volume
0.00
52-wk high
€200.00
52-wk low
€87.00
No. of employees
47
News stories
From sources across the web
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
FoundedSep 1987
HeadquartersJupiter, Florida, United States
SectorPharmaceutical industry
Websiteligand.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
45.33M
47.63M
115.46M
59.67M
Cost of goods sold
54.93M
9.47M
24.82M
6.50M
Cost of revenue
54.93M
9.47M
24.82M
6.50M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.80M
20.18M
28.45M
25.03M
Operating expense
27.06M
28.43M
36.54M
33.12M
Total operating expenses
81.99M
37.91M
61.36M
39.63M
Operating income
-36.66M
9.72M
54.10M
20.04M
Other non operating income
-2.06M
96.00K
390.00K
1.48M
EBT including unusual items
-50.18M
11.22M
141.14M
56.78M
EBT excluding unusual items
-37.81M
10.28M
57.45M
116.80M
Income tax expense
-7.73M
6.38M
23.86M
12.00M
Effective tax rate
15.40%
56.81%
16.91%
21.13%
Other operating expenses
-
-
-
-
Net income
-42.45M
4.85M
117.27M
44.78M
Net profit margin
-93.64%
10.18%
101.57%
75.06%
Earnings per share
1.33
1.60
3.09
2.02
Interest and investment income
1.77M
1.62M
3.87M
6.39M
Interest expense
-867.00K
-1.15M
-910.00K
-1.78M
Net interest expenses
904.00K
468.00K
2.96M
4.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.35M
17.82M
63.26M
28.25M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer